MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-05-2026
NextCure EV/EBITDA Ratio 2011-2026 | NXTC
Annual EV/EBITDA Ratio NextCure
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.03 | -7.67 | -18.8 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.03 | -18.8 | -9.49 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-0.591 | - | 2.43 % | $ 254 M |  Germany |
 |
Grifols, S.A.
GRFS
|
13.7 | $ 7.68 | - | $ 6.83 B |  Spain |
 |
Altimmune
ALT
|
-1.66 | $ 3.47 | 3.74 % | $ 306 M |  USA |
 |
Amgen
AMGN
|
10.7 | - | - | $ 188 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
17.3 | - | - | $ 915 M | USA |
 |
I-Mab
IMAB
|
595 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
10.7 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
4.22 K | - | 2.54 % | $ 160 B |  France |
 |
Heron Therapeutics
HRTX
|
-4.31 | - | - | $ 130 M | USA |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-15.7 | $ 218.0 | -1.75 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
0.796 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.42 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.546 | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
1.84 | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
4.4 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-1.85 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
0.777 | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
-3.38 | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-0.0369 | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
1.8 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
14 | - | - | - |  Russia |
 |
Incyte Corporation
INCY
|
24 | $ 90.75 | -0.03 % | $ 17.7 B | USA |
 |
Inovio Pharmaceuticals
INO
|
-2.19 | $ 1.57 | -0.63 % | $ 34.8 M | USA |
 |
Avenue Therapeutics
ATXI
|
0.871 | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.32 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-3.39 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-82.4 | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
0.785 | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
-8.81 | $ 12.91 | 1.33 % | $ 778 M | USA |
 |
Atreca
BCEL
|
-2.76 | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
8 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-208 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Inventiva S.A.
IVA
|
-9.77 | $ 6.11 | 5.71 % | $ 138 M | France |
 |
Calithera Biosciences
CALA
|
-7.96 | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
-6.7 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-0.721 | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
0.0235 | - | -74.18 % | $ 955 K | USA |
 |
Checkpoint Therapeutics
CKPT
|
-0.833 | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
-3.86 | - | -7.23 % | $ 13 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-3.44 | $ 16.73 | -1.59 % | $ 831 M | Britain |
 |
Aeglea BioTherapeutics
AGLE
|
-4.27 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-7.74 | - | - | $ 867 M | Germany |
 |
Denali Therapeutics
DNLI
|
-14.1 | $ 21.04 | 4.31 % | $ 3.46 B | USA |
 |
Kamada Ltd.
KMDA
|
-386 | $ 8.27 | 0.24 % | $ 260 M | Israel |
 |
Karyopharm Therapeutics
KPTI
|
-8.17 | $ 6.93 | -9.17 % | $ 845 K | USA |
 |
Keros Therapeutics
KROS
|
-20.3 | $ 11.17 | 1.92 % | $ 416 M | USA |
 |
Akero Therapeutics
AKRO
|
-4.64 | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-3.41 | $ 4.3 | 1.37 % | $ 714 M | Canada |
 |
Akouos
AKUS
|
-1.13 | - | 0.23 % | $ 488 M | USA |